2 Interactions found for:

The following applies to the ingredients: Amoxicillin (found in Augmentin)

Use is recommended only if clearly needed and the benefit outweighs the risk.

AU TGA pregnancy category: A
US FDA pregnancy category: B

Comments: May reduce efficacy of oral contraceptives.

Animal studies have failed to reveal evidence of teratogenicity, impaired fertility, or fetal harm. The effects during labor and delivery are unknown. There are no controlled data in human pregnancy.

AU TGA pregnancy category A: Drugs which have been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the fetus having been observed.

US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

The following applies to the ingredients: Amoxicillin-Clavulanate (found in Augmentin)

Amoxicillin-clavulanate has been assigned to pregnancy category B by the FDA. Animal studies failed to reveal any evidence of teratogenicity. There are no controlled data in human pregnancies. The results of a study suggest an increased risk of necrotizing enterocolitis in neonates if amoxicillin-clavulanate is given prophylactically to women with premature rupture of membranes. Amoxicillin-clavulanate should only be given during pregnancy when need has been clearly established.

In the Collaborative Perinatal Project involving 50,282 mother-child pairs, there were 3,546 mother-child pairs exposed to penicillin derivatives in the first trimester. As a group, there was no significant increase in the risk of malformations.

In the Michigan Medicaid Birth Defects Study involving 229,101 pregnancies from 1985 to 1992, there were 8,538 first trimester exposures to amoxicillin. Overall, 317 cases of birth defects were observed (363 expected). There was no evidence of an association between first trimester use of amoxicillin and major groups of malformations.

In the Michigan Medicaid Birth Defects Study, there were 556 first trimester exposures to clavulanate. Overall, 24 cases of birth defects were observed (24 expected). Two cases of spina bifida occurred compared with only 0.3 cases expected, representing a statistically significant increase in the incidence of this anomaly.

The following applies to the ingredients: Amoxicillin (found in Augmentin)

Use is considered acceptable; caution is recommended.

Excreted into human milk: Yes (in small amounts)

Comments: Rash and disruption of the infant's gastrointestinal flora resulting in diarrhea or thrush have been reported, rarely.

Following a single oral dose of 1 g in 6 women, peak milk levels of this drug occurred at 4 to 5 hours after the dose. Average milk levels were 0.69 mg/L (range 0.46 to 0.88 mg/L) at 4 hours and 0.81 mg/L (range 0.39 to 1.3 mg/L) at 5 hours after the dose. From this data, it is expected that an exclusively breastfed infant would receive a maximum of about 0.1 mg/kg/day with a maternal dose of 500 mg 3 times a day (about 0.25% to 0.5% of a typical infant dose).

The following applies to the ingredients: Amoxicillin-Clavulanate (found in Augmentin)

Amoxicillin is excreted into human milk in small amounts and is considered compatible with breast-feeding by the American Academy of Pediatrics. Clavulanate has not been detected in human milk. Adverse effects in the nursing infant are unlikely. The manufacturer recommends caution when amoxicillin-clavulanate is administered to a nursing woman.

In one study, six women were administered a single 1000 mg dose of amoxicillin on the third postpartum day. Amoxicillin milk concentrations ranged from 0.10 to 0.81 mcg/mL, with a peak concentration measured at 5 hours post-dose. The milk to maternal serum concentration ratio ranged from 0.013 to 0.043.